# A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

> **NCT06340958** · PHASE2 · COMPLETED · sponsor: **Clexio Biosciences Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Adjunctive Treatment of Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** CLE-100
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06340958
- **Lead sponsor:** Clexio Biosciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-18
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-11-25
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06340958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06340958, "A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06340958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*